MedPath

Yangxinshi Tablet Intervention for Exercise Capacity in Patients With Chronic Coronary Syndrome

Phase 4
Recruiting
Conditions
Chronic Coronary Syndrome
Interventions
Drug: Yangxinshi tablet
Other: Basic medication
Registration Number
NCT06171061
Lead Sponsor
Shandong First Medical University
Brief Summary

This study is a prospective, multicentre, randomized, open-label, blinded-endpoint clinical trial to evaluate the efficacy and safety of Yangxinshi tablets in the treatment of patients with chronic coronary syndrome (CCS).

Detailed Description

This study plans to enrol 1200 CCS patients. A central randomized control group will be set up. The experimental and control groups will be populated at a 3:1 ratio. In addition to basic medication, the experimental group will be given Yangxinshi tablets (three tablets each time, three times a day); the control group will be given basic medication only. The treatment period is 24 weeks. The primary efficacy indicator is the 6-minute walking distance (6MWD).

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1200
Inclusion Criteria
  1. age 18-75 years;
  2. CCS patients in stable condition and clearly diagnosed by coronary artery imaging (at least one vessel stenosis ≥ 50%): stable angina, ischaemic cardiomyopathy, asymptomatic or stable symptoms, occult coronary heart disease, acute coronary syndrome (ACS), or >3 months after coronary revascularization;
  3. moderately to severely limited exercise tolerance: the maximum 6MWD is < 450 m, or the metabolic equivalent (MET) as measured by treadmill cardiopulmonary exercise testing is < 5 METs;
  4. voluntary participation and signing of informed consent.
Exclusion Criteria
  1. absolute or relative contraindications for the treadmill cardiopulmonary exercise test or 6-minute walk test (6MWT);
  2. serious primary diseases, mental diseases, or malignant tumours that affect lifespan;
  3. pregnancy, intended or suspected pregnancy, miscarriage, breastfeeding, or delivery in the last 6 months;
  4. subjects not suitable for this study in the opinion of the researchers, such as subjects who are participating in other drug clinical trials or intervention studies.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Experimental groupYangxinshi tabletbasic medication + Yangxinshi tablet
Control groupBasic medicationbasic medication.
Primary Outcome Measures
NameTimeMethod
6MWD24 weeks after treatment

The 6-min walking distance

Secondary Outcome Measures
NameTimeMethod
MACCEafter 4, 8, 12, 16, 20, and 24 weeks of treatment

incidence of major adverse cardiovascular and cerebrovascular events (MACCE)

Borg scale24 weeks after treatment

score range: 0\~10,higher scores mean a worse outcome.

Trial Locations

Locations (32)

Zhengzhou Seventh People's Hospital

🇨🇳

Zhengzhou, Henan, China

Binzhou Medical University Hospital

🇨🇳

Binzhou, Shandong, China

Binzhou People's Hospital

🇨🇳

Binzhou, Shandong, China

Jinan Central Hospital

🇨🇳

Jinan, Shandong, China

Longkou People Hosptial

🇨🇳

Longkou, Shandong, China

Hospital of Cardiovascular Diseases Affiliated to Qingdao University

🇨🇳

Qingdao, Shandong, China

Shapingba District People's Hospital of Chongqing

🇨🇳

Chongqing, Chongqing, China

Dezhou Municiple Hospital

🇨🇳

Dezhou, Shandong, China

Feicheng People's Hospital

🇨🇳

Feicheng, Shandong, China

Pingyuan County first People's Hospital

🇨🇳

Dezhou, Shandong, China

Shandong Health Group Feicheng Hospital

🇨🇳

Feicheng, Shandong, China

Affiliated Hospital of Shandong University of Traditional Chinese Medicine

🇨🇳

Jinan, Shandong, China

Jinan Zhangqiu District People's Hospital

🇨🇳

Jinan, Shandong, China

Shandong Provincial Hospital Affiliated to Shandong First Medical University

🇨🇳

Jinan, Shandong, China

The Fourth People's Hospital of Jinan

🇨🇳

Jinan, Shandong, China

Gaotang County People's Hospital

🇨🇳

Liaocheng, Shandong, China

Liaocheng Hospital of Traditional Chinese Medicine

🇨🇳

Liaocheng, Shandong, China

Liaocheng People's Hospital

🇨🇳

Liaocheng, Shandong, China

Linyi People's Hospital

🇨🇳

Linyi, Shandong, China

The Second People's Hospital of Liaocheng

🇨🇳

Liaocheng, Shandong, China

Linqing City People's Hospital

🇨🇳

Linqing, Shandong, China

Affiliated Hospital of Qingdao University

🇨🇳

Qingdao, Shandong, China

Qingdao Fuwai Hospital

🇨🇳

Qingdao, Shandong, China

Qingdao Central Hospital

🇨🇳

Qingdao, Shandong, China

Qingdao Municipal Hospital

🇨🇳

Qingdao, Shandong, China

Shandong University Qilu Hospital Qingdao District

🇨🇳

Qingdao, Shandong, China

Xintai People's Hospital

🇨🇳

Taian, Shandong, China

The Second Affiliated Hospital of Shandong First Medical University

🇨🇳

Taian, Shandong, China

Weifang City People's Hospital

🇨🇳

Weifang, Shandong, China

Tengzhou Central People's Hospital

🇨🇳

Tengzhou, Shandong, China

Weifang City Yidu Central Hospital

🇨🇳

Weifang, Shandong, China

Yantai Hospital of Traditional Chinese Medicine

🇨🇳

Yantai, Shandong, China

© Copyright 2025. All Rights Reserved by MedPath